272 related articles for article (PubMed ID: 38307865)
21. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
22. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
Holstein SA; Grant SJ; Wildes TM
J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
[TBL] [Abstract][Full Text] [Related]
24. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
25. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
[TBL] [Abstract][Full Text] [Related]
26. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
[TBL] [Abstract][Full Text] [Related]
27. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
[TBL] [Abstract][Full Text] [Related]
28. GPRC5D-Directed CAR Yields 100% Response Rate.
Cancer Discov; 2022 Aug; 12(8):OF3. PubMed ID: 35748592
[TBL] [Abstract][Full Text] [Related]
29. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
30. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Laheij AMGA; van de Donk NWCJ
Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
[TBL] [Abstract][Full Text] [Related]
31. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B; Miett T; Patel SA
Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
[TBL] [Abstract][Full Text] [Related]
32. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
33. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Martino M; Paviglianiti A
Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948
[No Abstract] [Full Text] [Related]
34. T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau P; Touzeau C
Blood; 2022 Jun; 139(26):3681-3687. PubMed ID: 35404996
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
36. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Fernández de Larrea C; Staehr M; Lopez AV; Ng KY; Chen Y; Godfrey WD; Purdon TJ; Ponomarev V; Wendel HG; Brentjens RJ; Smith EL
Blood Cancer Discov; 2020 Sep; 1(2):146-154. PubMed ID: 33089218
[TBL] [Abstract][Full Text] [Related]
37. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
38. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
[TBL] [Abstract][Full Text] [Related]
39. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab.
Lery M; Perrot A; Ortiz-Brugués A; Vigarios E; Anghel D; Bories P; Sibaud V
J Am Acad Dermatol; 2024 Feb; 90(2):376-377. PubMed ID: 37742842
[No Abstract] [Full Text] [Related]
40. Current use of bispecific antibodies to treat multiple myeloma.
Lee H; Neri P; Bahlis NJ
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):332-339. PubMed ID: 38066842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
